End-Truncated LAMB1 Causes a Hippocampal Memory Defect and a Leukoencephalopathy.


Journal

Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449

Informations de publication

Date de publication:
12 2021
Historique:
revised: 01 10 2021
received: 18 03 2021
accepted: 02 10 2021
pubmed: 5 10 2021
medline: 15 12 2021
entrez: 4 10 2021
Statut: ppublish

Résumé

The majority of patients with a familial cerebral small vessel disease (CSVD) referred for molecular screening do not show pathogenic variants in known genes. In this study, we aimed to identify novel CSVD causal genes. We performed a gene-based collapsing test of rare protein-truncating variants identified in exome data of 258 unrelated CSVD patients of an ethnically matched control cohort and of 2 publicly available large-scale databases, gnomAD and TOPMed. Western blotting was used to investigate the functional consequences of variants. Clinical and magnetic resonance imaging features of mutated patients were characterized. We showed that LAMB1 truncating variants escaping nonsense-mediated messenger RNA decay are strongly overrepresented in CSVD patients, reaching genome-wide significance (p < 5 × 10 These findings are important for diagnosis and clinical care, to avoid unnecessary and sometimes invasive investigations, and also from a mechanistic point of view to understand the role of extracellular matrix proteins in neuronal homeostasis. ANN NEUROL 2021;90:962-975.

Identifiants

pubmed: 34606115
doi: 10.1002/ana.26242
doi:

Substances chimiques

LAMB1 protein, human 0
Laminin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

962-975

Subventions

Organisme : Agence Nationale de la Recherche
ID : ANR-16-RHUS- 0004

Informations de copyright

© 2021 American Neurological Association.

Références

Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689-701.
Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol 2019;18:684-696.
Sarbu N, Shih RY, Jones RV, et al. White matter diseases with radiologic-pathologic correlation. Radiographics 2016;36:1426-1447.
Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707-710.
Verdura E, Hervé D, Scharrer E, et al. Heterozygous HTRA1 mutations are associated with autosomal dominant cerebral small vessel disease. Brain 2015;138:2347-2358.
Verdura E, Hervé D, Bergametti F, et al. Disruption of a miR-29 binding site leading to COL4A1 upregulation causes pontine autosomal dominant microangiopathy with leukoencephalopathy. Ann Neurol 2016;80:741-753.
Mancuso M, Arnold M, Bersano A, et al. Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European academy of neurology. Eur J Neurol 2020;27:909-927.
Rutten-Jacobs LCA, Rost NS. Emerging insights from the genetics of cerebral small-vessel disease. Ann N Y Acad Sci 2020;1471:5-17.
Naba A, Clauser KR, Hoersch S, et al. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics 2012;11:M111.014647.
Joutel A, Haddad I, Ratelade J, Nelson MT. Perturbations of the cerebrovascular matrisome: a convergent mechanism in small vessel disease of the brain? J Cereb Blood Flow Metab 2016;36:143-157.
Debette S, Strbian D, Wardlaw J, et al. Fourth European stroke science workshop. Eur Stroke J 2018;3:206-219.
Lee S, Abecasis GR, Boehnke M, Lin X. Rare-variant association analysis: study designs and statistical tests. Am J Hum Genet 2014;95:5-23.
Nicolae DL. Association tests for rare variants. Annu Rev Genomics Hum Genet 2016;17:117-130.
Povysil G, Petrovski S, Hostyk J, et al. Rare-variant collapsing analyses for complex traits: guidelines and applications. Nat Rev Genet 2019;20:747-759.
Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet 1999;8:1893-1900.
Dyle MC, Kolakada D, Cortazar MA, Jagannathan S. How to get away with nonsense: mechanisms and consequences of escape from nonsense-mediated RNA decay. WIREs RNA 2020;11:e1560.
Genin E, Redon R, Deleuze J-F, et al. The French exome (FREX) project: a population-based panel of Exomes to help filter out common local variants. Genet Epidemiol 2017;41:691-691.
Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. ArXiv E-Prints 2013;1303:arXiv:1303.3997.
van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline. Curr Protoc Bioinformatics 2013;43:11.10.1-11.10.33.
DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011;43:491-498.
Tarasov A, Vilella AJ, Cuppen E, et al. Sambamba: fast processing of NGS alignment formats. Bioinformatics 2015;31:2032-2034.
Picard Toolkit repository. Picard Toolkit repository [Internet]. 2019. http://broadinstitute.github.io/picard/
Hard-filtering germline short variants [Internet]. GATK [date unknown]. https://gatk.broadinstitute.org/hc/en-us/articles/360035890471-Hard-filtering-germline-short-variants
McLaren W, Gil L, Hunt SE, et al. The Ensembl variant effect predictor. Genome Biol 2016;17:122.
Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-575.
Leutenegger A-L, Prum B, Génin E, et al. Estimation of the inbreeding coefficient through use of genomic data. Am J Hum Genet 2003;73:516-523.
Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020;581:434-443.
Kowalski MH, Qian H, Hou Z, et al. Use of >100,000 NHLBI trans-Omics for precision medicine (TOPMed) consortium whole genome sequences improves imputation quality and detection of rare variant associations in admixed African and Hispanic/Latino populations. PLoS Genet 2019;15:e1008500.
Taliun D, Harris DN, Kessler MD, et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed program. Nature 2021;590:290-299.
Kurosaki T, Maquat LE. Nonsense-mediated mRNA decay in humans at a glance. J Cell Sci 2016;129:461-467.
Lindeboom RGH, Supek F, Lehner B. The rules and impact of nonsense-mediated mRNA decay in human cancers. Nat Genet 2016;48:1112-1118.
Lindeboom RGH, Vermeulen M, Lehner B, Supek F. The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy. Nat Genet 2019;51:1645-1651.
Le Hir H, Gatfield D, Izaurralde E, Moore MJ. The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay. EMBO J 2001;20:4987-4997.
Nagy E, Maquat LE. A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. Trends Biochem Sci 1998;23:198-199.
Traynelis J, Silk M, Wang Q, et al. Optimizing genomic medicine in epilepsy through a gene-customized approach to missense variant interpretation. Genome Res 2017;27:1715-1729.
Gelfman S, Dugger S, Moreno C, et al. A new approach for rare variation collapsing on functional protein domains implicates specific genic regions in ALS. Genome Res 2019;29:809-818.
Cameron-Christie S, Wolock CJ, Groopman E, et al. Exome-based rare-variant analyses in CKD. J Am Soc Nephrol 2019;30:1109-1122.
Nirwane A, Yao Y. Laminins and their receptors in the CNS. Biol Rev 2019;94:283-306.
Taniguchi Y, Ido H, Sanzen N, et al. The C-terminal region of laminin beta chains modulates the integrin binding affinities of laminins. J Biol Chem 2009;284:7820-7831.
Pulido D, Hussain S-A, Hohenester E. Crystal structure of the Heterotrimeric integrin-binding region of Laminin-111. Structure 2017;25:530-535.
Liu YB, Tewari A, Salameh J, et al. A dystonia-like movement disorder with brain and spinal neuronal defects is caused by mutation of the mouse laminin β1 subunit, Lamb1. Elife 2015;4:e11102.
Yin Y, Kikkawa Y, Mudd JL, et al. Expression of laminin chains by central neurons: analysis with gene and protein trapping techniques. Genesis 2003;36:114-127.
Radmanesh F, Caglayan AO, Silhavy JL, et al. Mutations in LAMB1 cause cobblestone brain malformation without muscular or ocular abnormalities. Am J Hum Genet 2013;92:468-474.
Tonduti D, Dorboz I, Renaldo F, et al. Cystic leukoencephalopathy with cortical dysplasia related to LAMB1 mutations. Neurology 2015;84:2195-2197.
Okazaki T, Saito Y, Hayashida T, et al. Bilateral cerebellar cysts and cerebral white matter lesions with cortical dysgenesis: expanding the phenotype of LAMB1 gene mutations. Clin Genet 2018;94:391-392.
Yasuda R, Yoshida T, Mizuta I, et al. Adult-onset leukoencephalopathy with homozygous LAMB1 missense mutation. Neurol Genet 2020;6:e442.
Chen Z-L, Indyk JA, Strickland S. The hippocampal laminin matrix is dynamic and critical for neuronal survival. Mol Biol Cell 2003;14:2665-2676.
Yousif LF, di Russo J, Sorokin L. Laminin isoforms in endothelial and perivascular basement membranes. Cell Adh Migr 2013;7:101-110.
Dityatev A, Schachner M, Sonderegger P. The dual role of the extracellular matrix in synaptic plasticity and homeostasis. Nat Rev Neurosci 2010;11:735-746.
Ma J, Ma C, Li J, et al. Extracellular matrix proteins involved in Alzheimer's disease. Chem Weinh Bergstr Ger 2020;26:12101-12110.

Auteurs

Chaker Aloui (C)

Université de Paris, INSERM UMR 1141 NeuroDiderot, Paris, France.

Dominique Hervé (D)

Université de Paris, INSERM UMR 1141 NeuroDiderot, Paris, France.
AP-HP, Groupe Hospitalier Saint-Louis Lariboisière-Fernand-Widal, Service de Neurologie, Centre de Référence des Maladies Vasculaires Rares du Cerveau et de l'Œil (CERVCO), Paris, France.

Gaelle Marenne (G)

Université de Brest, Inserm, EFS, CHU Brest, UMR 1078, GGB, Brest, France.

Florian Savenier (F)

Université de Paris, INSERM UMR 1141 NeuroDiderot, Paris, France.

Kilan Le Guennec (K)

Université de Paris, INSERM UMR 1141 NeuroDiderot, Paris, France.

Francoise Bergametti (F)

Université de Paris, INSERM UMR 1141 NeuroDiderot, Paris, France.

Edgard Verdura (E)

Université de Paris, INSERM UMR 1141 NeuroDiderot, Paris, France.

Thomas E Ludwig (TE)

Université de Brest, Inserm, EFS, CHU Brest, UMR 1078, GGB, Brest, France.

Jessica Lebenberg (J)

Université de Paris, INSERM UMR 1141 NeuroDiderot, Paris, France.

Waliyde Jabeur (W)

Université de Paris, INSERM UMR 1141 NeuroDiderot, Paris, France.

Hélène Morel (H)

Université de Paris, INSERM UMR 1141 NeuroDiderot, Paris, France.
AP-HP, Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis, Paris, France.

Thibault Coste (T)

Université de Paris, INSERM UMR 1141 NeuroDiderot, Paris, France.
AP-HP, Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis, Paris, France.

Geneviève Demarquay (G)

Hôpital Neurologique, Hospices Civils de Lyon, Lyon Neuroscience Research Center (CRNL), Brain Dynamics and Cognition Team (Dycog), INSERM U1028, CNRS UMR5292, Lyon, France.

Panagiotis Bachoumas (P)

Centre Hospitalier Public Du Cotentin, Cherbourg-en-Cotentin, France.

Julien Cogez (J)

CHU Caen, Department of Neurology, CHU de Caen Côte de Nacre, Caen, France.

Guillaume Mathey (G)

Neurology Unit, University Hospital of Nancy, Nancy, France.

Emilien Bernard (E)

Department of Neurology, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France.
Institut NeuroMyoGène, INSERM-CNRS-UMR, Université Claude Bernard, Lyon, France.

Hugues Chabriat (H)

Université de Paris, INSERM UMR 1141 NeuroDiderot, Paris, France.
AP-HP, Groupe Hospitalier Saint-Louis Lariboisière-Fernand-Widal, Service de Neurologie, Centre de Référence des Maladies Vasculaires Rares du Cerveau et de l'Œil (CERVCO), Paris, France.

Emmanuelle Génin (E)

Université de Brest, Inserm, EFS, CHU Brest, UMR 1078, GGB, Brest, France.

Elisabeth Tournier-Lasserve (E)

Université de Paris, INSERM UMR 1141 NeuroDiderot, Paris, France.
AP-HP, Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH